Israeli biopharmaceutical company Can-Fite BioPharma announced successful results in the preclinical trial of CF101 – a drug for the treatment of inflammations of the uvea, which is the middle layer of the eye. Such inflammations can result in blindness and according to the company are the fifth or sixth leading causes of blindness in the US.
Related posts
People With Autism Experience Higher Intensity Pain
January 30, 2023
Israeli Innovation At New Bahraini Hospital
January 30, 2023
US Car Giant Signs Up For AI Vehicle Inspections
January 29, 2023
Considerate Partners Are Less Likely To Cheat
January 29, 2023
Facebook comments